NCT00379340
Clinical Trial Information
Trial Number: NCT00379340 (ClinicalTrials.gov)
Disease Type:
- Kidney Neoplasm - Wilms Tumor
Trial Title:
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Study ID:
AREN0533
Images are available?:
Yes
Imaging data can be requested via the NCTN/NCORP Data Archive. To view imaging data details before requesting data here, visit:
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| 31449468-D6 | There are six datasets associated with PMID 31449468, which presents primary outcome data for patients enrolled on AREN0532 and AREN0533 with loss of heterozygosity of chromosomes 1p and 16q. These data contain information on the number of NWTS-5 patients with LOH. Each row corresponds with the results of a single patient. Additional data from AREN0532 is associated with PMID 27811504, which reports on patients with very low-risk Wilms tumor, and with PMID 29211618, which reports on patients with stage III Wilms tumor without LOH of 1p and 16q. Additional data from AREN0533 is associated with PMID 29659330, which reports on patients with stage IV Wilms tumor with lung metastases. |
| 31449468-D5 | There are six datasets associated with PMID 31449468, which presents primary outcome data for patients enrolled on AREN0532 and AREN0533 with loss of heterozygosity of chromosomes 1p and 16q. This dataset contains the data for incidences of adverse events shown in supplemental table 2 and 3 (AREN0532/AREN0533). Each row corresponds with a single adverse event. Additional data from AREN0532 is associated with PMID 27811504, which reports on patients with very low-risk Wilms tumor, and with PMID 29211618, which reports on patients with stage III Wilms tumor without LOH of 1p and 16q. Additional data from AREN0533 is associated with PMID 29659330, which reports on patients with stage IV Wilms tumor with lung metastases. |
| 31449468-D4 | There are six datasets associated with PMID 31449468, which presents primary outcome data for patients enrolled on AREN0532 and AREN0533 with loss of heterozygosity of chromosomes 1p and 16q. This dataset contains the data for table 2 in the manuscript and the consort diagram (AREN03B). Each row corresponds with the results of a single patient. Additional data from AREN0532 is associated with PMID 27811504, which reports on patients with very low-risk Wilms tumor, and with PMID 29211618, which reports on patients with stage III Wilms tumor without LOH of 1p and 16q. Additional data from AREN0533 is associated with PMID 29659330, which reports on patients with stage IV Wilms tumor with lung metastases. |
| 31449468-D3 | There are six datasets associated with PMID 31449468, which presents primary outcome data for patients enrolled on AREN0532 and AREN0533 with loss of heterozygosity of chromosomes 1p and 16q. This dataset contains the data for supplemental figure 2 which shows outcomes for patients with lung metastases on AREN0533, regardless of LOH of 1p and 16 status. Each row corresponds with the results for a single patient. Additional data from AREN0532 is associated with PMID 27811504, which reports on patients with very low-risk Wilms tumor, and with PMID 29211618, which reports on patients with stage III Wilms tumor without LOH of 1p and 16q. Additional data from AREN0533 is associated with PMID 29659330, which reports on patients with stage IV Wilms tumor with lung metastases. |
| 31449468-D2 | There are six datasets associated with PMID 31449468, which presents primary outcome data for patients enrolled on AREN0532 and AREN0533 with loss of heterozygosity of chromosomes 1p and 16q. This dataset contains the results of NWTS-5 as presented in the manuscript. Each row corresponds with the results for a single patient. Additional data from AREN0532 is associated with PMID 27811504, which reports on patients with very low-risk Wilms tumor, and with PMID 29211618, which reports on patients with stage III Wilms tumor without LOH of 1p and 16q. Additional data from AREN0533 is associated with PMID 29659330, which reports on patients with stage IV Wilms tumor with lung metastases. |
| 31449468-D1 | There are six datasets associated with PMID 31449468, which presents primary outcome data for patients enrolled on AREN0532 and AREN0533 with loss of heterozygosity of chromosomes 1p and 16q. This dataset contains the main results of the study (AREN0532/AREN0533). Each row corresponds with the results for a single patient. Additional data from AREN0532 is associated with PMID 27811504, which reports on patients with very low-risk Wilms tumor, and with PMID 29211618, which reports on patients with stage III Wilms tumor without LOH of 1p and 16q. Additional data from AREN0533 is associated with PMID 29659330, which reports on patients with stage IV Wilms tumor with lung metastases. |
| NCT00379340-D4 | NCT00379340-D4 These data provide specific incidences of adverse events. “NCT00379340-D4” is necessary for recreating table A3 in the manuscript. Each row corresponds to a single Adverse Event. |
| NCT00379340-D3 | NCT00379340-D3 These data provide specific incidences of adverse events. “NCT00379340-D3” is necessary for recreating table A2, each row corresponds to a single Adverse Event. |
| NCT00379340-D2 | “NCT00379340-D2” is required for recreating the results of NWTS-5 as presented in the manuscript. Each row corresponds with the results for a single patient. The datasets also provide patient data necessary for recreating the experimental cohorts as well as characteristics of the initial disease, treatment, and outcomes. |
| NCT00379340-D1 | “NCT00379340-D1” is required for recreating the main results of AREN0533 study. Each row corresponds with the results for a single patient. The datasets also provide patient data necessary for recreating the experimental cohorts as well as characteristics of the initial disease, treatment, and outcomes. |
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®